Clinical Trials Browser

Ovarian Neoplasms × durvalumab × 90 days × Clear all

NCT02264678 2026-05-12

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

Phase 1 Active not recruiting

Ovarian Neoplasms

NCT04918186 2026-05-12

IPROC

Phase 2 Recruiting

Ovarian Neoplasms

NCT02734004 2026-04-20

MEDIOLA

Phase 1/2 Active not recruiting

264 enrolled 32 charts

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma